Is ALGS or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -1,919.68% -139.47% -90.88% Genelux N/A -174.55% -123.65%

Do analysts recommend ALGS or THAR?

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 639.82%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Aligos Therapeutics (ALGS) Competitors

$5.14 -0.11 (-2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$5.14 0.00 (-0.10%)

As of 04:10 PM Eastern

Compare

ALGS vs. GNLX, BDTX, THAR, CRDF, and VTVT

Should you buy Aligos Therapeutics stock or one of its competitors? MarketBeat compares Aligos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aligos Therapeutics include Genelux (GNLX), Black Diamond Therapeutics (BDTX), Tharimmune (THAR), Cardiff Oncology (CRDF), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does Aligos Therapeutics compare to Genelux?

Aligos Therapeutics (NASDAQ:ALGS) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Aligos Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 639.82%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 500.00%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Genelux	N/A	-174.55%	-123.65%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genelux had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.22 beat Genelux's score of 0.91 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Genelux	Positive

Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Aligos Therapeutics has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.71	-$24.19M	-$8.69	N/A
Genelux	$8K	16,815.00	-$32.15M	-$0.85	N/A

Summary

Aligos Therapeutics beats Genelux on 13 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to Black Diamond Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Black Diamond Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Black Diamond Therapeutics' return on equity of -30.18% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 639.82%. Black Diamond Therapeutics has a consensus price target of $10.00, indicating a potential upside of 377.33%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 1.22 beat Black Diamond Therapeutics' score of 1.13 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Black Diamond Therapeutics	Positive

Black Diamond Therapeutics has higher revenue and earnings than Aligos Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.71	-$24.19M	-$8.69	N/A
Black Diamond Therapeutics	$70M	1.71	$22.37M	-$0.77	N/A

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aligos Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Aligos Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to Tharimmune?

Aligos Therapeutics (NASDAQ:ALGS) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aligos Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

In the previous week, Aligos Therapeutics had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Aligos Therapeutics and 0 mentions for Tharimmune. Aligos Therapeutics' average media sentiment score of 1.22 beat Tharimmune's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Tharimmune	Neutral

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 639.82%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tharimmune has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.71	-$24.19M	-$8.69	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Tharimmune has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Tharimmune	N/A	-588.45%	-264.41%

Summary

Aligos Therapeutics beats Tharimmune on 12 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Cardiff Oncology?

Aligos Therapeutics (NASDAQ:ALGS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aligos Therapeutics has a net margin of -1,919.68% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Aligos Therapeutics has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.71	-$24.19M	-$8.69	N/A
Cardiff Oncology	$590K	162.81	-$45.85M	-$0.67	N/A

In the previous week, Cardiff Oncology had 7 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.22 beat Cardiff Oncology's score of 0.17 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Cardiff Oncology	Neutral

Aligos Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 639.82%. Cardiff Oncology has a consensus price target of $8.75, suggesting a potential upside of 522.78%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aligos Therapeutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aligos Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

Aligos Therapeutics beats Cardiff Oncology on 11 of the 17 factors compared between the two stocks.

How does Aligos Therapeutics compare to vTv Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Aligos Therapeutics has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	14.71	-$24.19M	-$8.69	N/A
vTv Therapeutics	$1.02M	127.24	-$26.97M	-$0.93	N/A

Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 639.82%. vTv Therapeutics has a consensus target price of $53.00, indicating a potential upside of 60.90%. Given Aligos Therapeutics' higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

vTv Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. vTv Therapeutics' return on equity of 3.96% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
vTv Therapeutics	N/A	3.96%	2.86%

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 1.22 beat vTv Therapeutics' score of 0.94 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
vTv Therapeutics	Positive

Summary

Aligos Therapeutics beats vTv Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.21M	$3.28B	$6.25B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-0.60	17.91	22.28	24.19
Price / Sales	14.71	324.60	581.86	138.32
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	0.60	6.64	9.84	6.72
Net Income	-$24.19M	$24.20M	$3.57B	$337.19M
7 Day Performance	-7.07%	-3.17%	-1.15%	0.53%
1 Month Performance	-14.55%	0.57%	3.85%	5.10%
1 Year Performance	-12.54%	47.29%	27.43%	34.36%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	3.8716 of 5 stars	$5.20 -0.9%	$38.50 +639.8%	+0.0%	$32.21M	$2.19M	N/A	90	Positive News
GNLX Genelux	3.1665 of 5 stars	$3.01 +3.1%	$18.00 +498.0%	+20.4%	$134.97M	$10K	N/A	10	News Coverage
BDTX Black Diamond Therapeutics	2.6528 of 5 stars	$2.33 +2.2%	$10.00 +329.2%	-8.0%	$133.51M	$70M	N/A	90	Gap Up High Trading Volume
THAR Tharimmune	N/A	$3.52 +5.1%	N/A	+89.5%	$132.81M	N/A	N/A	2	Gap Up
CRDF Cardiff Oncology	2.1993 of 5 stars	$1.94 +9.0%	$10.10 +420.6%	-54.9%	$132.64M	$590K	N/A	20	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. GNLX, BDTX, THAR, CRDF, and VTVT

How does Aligos Therapeutics compare to Genelux?

Summary

How does Aligos Therapeutics compare to Black Diamond Therapeutics?

Summary

How does Aligos Therapeutics compare to Tharimmune?

Summary

How does Aligos Therapeutics compare to Cardiff Oncology?

Summary

How does Aligos Therapeutics compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. GNLX, BDTX, THAR, CRDF, and VTVT

How does Aligos Therapeutics compare to Genelux?

Do analysts recommend ALGS or GNLX?

Is ALGS or GNLX more profitable?

Do insiders and institutionals have more ownership in ALGS or GNLX?

Does the media favor ALGS or GNLX?

Which has more volatility and risk, ALGS or GNLX?

Which has better valuation & earnings, ALGS or GNLX?

Summary

How does Aligos Therapeutics compare to Black Diamond Therapeutics?

Is ALGS or BDTX more profitable?

Do analysts rate ALGS or BDTX?

Does the media favor ALGS or BDTX?

Which has higher earnings and valuation, ALGS or BDTX?

Do institutionals and insiders hold more shares of ALGS or BDTX?

Which has more volatility and risk, ALGS or BDTX?

Summary

How does Aligos Therapeutics compare to Tharimmune?

Do insiders and institutionals have more ownership in ALGS or THAR?

Which has more risk and volatility, ALGS or THAR?

Does the media prefer ALGS or THAR?

Do analysts recommend ALGS or THAR?

Which has higher earnings and valuation, ALGS or THAR?

Is ALGS or THAR more profitable?

Summary

How does Aligos Therapeutics compare to Cardiff Oncology?

Do institutionals & insiders have more ownership in ALGS or CRDF?

Is ALGS or CRDF more profitable?

Which has stronger earnings and valuation, ALGS or CRDF?

Does the media favor ALGS or CRDF?

Do analysts rate ALGS or CRDF?

Which has more volatility & risk, ALGS or CRDF?

Summary

How does Aligos Therapeutics compare to vTv Therapeutics?

Which has preferable earnings and valuation, ALGS or VTVT?

Which has more volatility and risk, ALGS or VTVT?

Do analysts rate ALGS or VTVT?

Is ALGS or VTVT more profitable?

Do institutionals and insiders believe in ALGS or VTVT?

Does the media prefer ALGS or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools